{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=therapy&page=17", "query": { "intervention": "therapy", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 2557, "total_pages": 256, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=therapy&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=therapy&page=16&page_size=10" }, "source": "local", "last_synced_at": "2026-10-16T17:52:48.539Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07061964", "title": "Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Muscle Invasive Bladder Urothelial Carcinoma", "Stage II Bladder Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cystoscopy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Photon Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Transurethral Resection of Bladder Tumor", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2025-11-25", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-14T02:30:14.122Z", "location_count": 181, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 146 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07061964" }, { "nct_id": "NCT07025226", "title": "Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Glioma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Fisetin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quercetin", "type": "DRUG" }, { "name": "Single Agent Therapy", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Topoisomerase-1 Inhibitor LMP744", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-08-12", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-13T18:42:40.029Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07025226" }, { "nct_id": "NCT06764095", "title": "Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Renal Pelvis and Ureter Urothelial Carcinoma", "Stage III Bladder Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Renal Pelvis and Ureter Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cystectomy", "type": "PROCEDURE" }, { "name": "Enfortumab Vedotin", "type": "DRUG" }, { "name": "Local Therapy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ureterectomy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2025-01-08", "completion_date": "2032-01-01", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-14T14:53:47.566Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06764095" }, { "nct_id": "NCT06660225", "title": "Deep Brain Stimulation for Refractory Obsessive-Compulsive Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obsessive-Compulsive Disorder" ], "interventions": [ { "name": "Medtronic Percept Deep Brain Stimulation Therapy [Sham Control Stimulation]", "type": "DEVICE" }, { "name": "Medtronic Percept Deep Brain Stimulation Therapy [Therapeutic stimulation]", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Nader Pouratian", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "22 Years to 75 Years" }, "enrollment_count": 10, "start_date": "2026-11", "completion_date": "2031-01", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-14T23:54:43.945Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06660225" }, { "nct_id": "NCT06470282", "title": "Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer", "Muscle-Invasive Bladder Carcinoma", "Stage II Bladder Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8" ], "interventions": [ { "name": "Computed Tomography (CT)", "type": "PROCEDURE" }, { "name": "Cystoscopy (CS)", "type": "PROCEDURE" }, { "name": "Enfortumab Vedotin", "type": "DRUG" }, { "name": "Intensity Modulated Radiation Therapy (IMRT)", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging (MRI)", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography (PET)", "type": "PROCEDURE" }, { "name": "Transurethral Resection of Bladder Tumor", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2025-03-31", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-15T23:30:43.973Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06470282" }, { "nct_id": "NCT06369285", "title": "A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone Receptor Positive HER-2 Negative Breast Cancer", "Metastatic Breast Cancer", "Recurrent Breast Cancer" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Endocrine therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Puma Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": "2024-11-19", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-16T17:52:48.539Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06369285" }, { "nct_id": "NCT06078709", "title": "Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage I Esophageal Adenocarcinoma AJCC v8", "Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Endoscopic Ultrasound", "type": "PROCEDURE" }, { "name": "Esophagogastroduodenoscopy", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2023-11-21", "completion_date": "2029-05-25", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-15T18:23:15.365Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06078709" }, { "nct_id": "NCT06000787", "title": "MCT for the Harvard/UCSF ROBIN Center", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Glioma, Childhood Brainstem", "Neuroblastoma" ], "interventions": [ { "name": "131I-Metaiodobenzylguanidine (MIBG)", "type": "RADIATION" }, { "name": "External beam radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 47, "start_date": "2023-09-19", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-15T03:42:53.753Z", "location_count": 2, "location_summary": "San Francisco, California • Boston, Massachusetts", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06000787" }, { "nct_id": "NCT05541016", "title": "De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma", "Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Diffusing Alpha-emitter Radiation Therapy", "type": "RADIATION" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Intensity-Modulated Proton Therapy", "type": "PROCEDURE" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Modified Barium Swallow Study", "type": "PROCEDURE" }, { "name": "Observation Activity", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 455, "start_date": "2023-03-20", "completion_date": "2029-09-06", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-15T09:56:21.049Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05541016" }, { "nct_id": "NCT07849465", "title": "Hyperbaric Oxygen Therapy for Veterans With TBI and PCS: A Biomarker Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "PTSD", "Post Concussive Symptoms", "Traumatic Brain Injury (TBI) Patients" ], "interventions": [ { "name": "Hyperbaric Oxygen Therapy (HBOT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Summit Hyperbarics and Wellness", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 34, "start_date": "2026-10-01", "completion_date": "2027-10-01", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-16T01:05:59.191Z", "location_count": 1, "location_summary": "Boise, Idaho", "locations": [ { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT07849465" } ] }